A nonreplicating adeno-associated virus, serotype SAN011, that expresses an artificial microRNA which reduces and degrades the DMPK mRNA trapping the RBPs was granted orphan designation as a treatment of myotonic dystrophy type 1, according to a post the FDA website. Sanofi US Services is listed as the sponsor.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Buy These Olympic Stocks, Say Wall Street Analysts
- Kymera Therapeutics jumps 10% to $35.09 after expanding phase 2 trials
- Kymera expands HS and AD Phase 2 trials following review
- Sanofi price target raised to EUR 111 from EUR 109 at Stifel
- PE firms weigh possible bids for Sanofi consumer unit, Bloomberg says